Prospective study of immunological factors in non-inflammatory bowel disease enterocutaneous fistulas

Abstract

BackgroundEnterocutaneous fistulas (ECF) are debilitating and usually result following complex abdominal surgery. While there is an association with inflammatory bowel disease (IBD), a large number of fistulas occur after surgery not related to IBD. The consequences of ECF include short bowel syndrome and the need for long term parenteral nutrition.ECF can heal spontaneously and in the case of IBD can be cured by medical therapy in some instances. Those that do not resolve spontaneously have to be cured by surgery which is complex and associated with a high morbidity. It is not considered traditional treatment to use the same medical therapy as in IBD to cure ECF caused by other conditions.A small case series has reported three patients with persistent ECF not related to IBD to have healed following use of Infliximab which is the treatment commonly used for ECF caused by IBD. Infliximab acts by inhibiting the activity of the inflammatory cytokine TNF- alpha. It is not known if this cytokine is present in ECF tissue in the absence of IBD.The aim of this study is to demonstrate the presence of inflammatory markers in tissue surrounding non-IBD ECF and in particular to quantify the presence of the cytokine TNF- alpha. We hypothesise that TNF - alpha levels are raised in non-IBD ECF.Methods/DesignTissue and serum from ECF of IBD and non-IBD patients will be prospectively collected at St. Mark's Hospital Intestinal Failure Unit. The control group will consist of patients undergoing colonoscopy for bowel cancer screening, with normal findings. Biopsies of the terminal ileum will be obtained from this group during colonoscopy. The fistula tract and serum cytokine profiles of interleukins (IL)-1a, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, TNF- alpha, IFN-y, MCP-1, EGF and VEGF will be assessed.DiscussionThis study aims to assess the presence or absence of TNF- alpha expression in the ECF tissue in non-IBD origin. If our hypothesis is correct we would then be able to study the use of the TNF- alpha inhibitor Infliximab as a therapeutic option in the treatment of non-IBD ECF. Secondary aims include assessing the spectrum of inflammatory cytokines and markers present in tissue and serum of non-IBD ECF when compared with IBD ECF and normal controls.Trial registrationISRCTN44000447

Adipose tissue-derived stem cells as a therapeutic strategy for enterocutaneous fistula: an experimental model study

“…TNF is a proinflammatory cytokine that induces the production of interleukin-1 (IL-1) and IL-6 cytokines, increases leukocyte mobility, and enhances capillary permeability, leading to a continuous inflammatory response that can hinder tissue healing. Therefore, therapies that can target this mechanism, such as administration of ASC, have the potential to facilitate the tissue healing process 2 , 40 , 41 .…”

Enterocutaneous fistulas and Crohn's disease: Clinical characteristics and response to treatment

“…In fact, there is currently a study under way in the United Kingdom that will evaluate the presence or absence of TNF expression on ECF. The results of these studies will help us learn the true efficacy of biological therapies in these patients (9).…”

Aplicação de células-tronco derivadas de tecido adiposo para tratamento de fístula enterocutânea em modelo experimental murino

“…Tanto as fístulas causadas por doenças inflamatórias intestinais quanto aquelas de outras origens apresentam elevada quantidade de TNF (Present et al, 1999;Cho, 2008;Rahbour et al, 2011). Essa substância apresenta importante atividade próinflamatória através da indução das citocinas Interleucina (IL)-1 e IL-6, aumento de leucócitos e também migração de células dos vasos sanguíneos por aumento da permeabilidade capilar (Lloyd;Windsor, 2006;Rahbour et al, 2011). Assim, essa contínua atividade inflamatória presente na FEC atua de forma contrária à cicatrização tecidual, abrindo espaço para outras terapias com efeito nesse mecanismo.…”